Previous research has shown that lung cancer patients could gain significant advantages from PD‐1/PD‐L1 inhibitors and that TMB is associated with outcomes with immunotherapies, but the correlation is still controversial [29]. The gene discussed is CD274; the disease is lung carcinoma.